Related Experiment Video
Updated: Jun 5, 2026

Probiotic Studies in Neonatal Mice Using Gavage
Published on: January 27, 2019
Use of prokinetics in the preterm infant
1Department of Paediatrics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong, China.
Insights
High-dose erythromycin may benefit premature infants with gastrointestinal dysmotility when used as rescue therapy. Lower doses and prophylactic use showed no benefit, but risks like antibiotic resistance require further study.
Area of Science:
- Neonatalogy
- Gastroenterology
- Pharmacology
Background:
- Functional gastrointestinal dysmotility is common in premature infants.
- Delayed enteral nutrition increases risks associated with parenteral nutrition.
- Conflicting evidence exists on prokinetic agents for preterm infants.
Purpose of the Study:
- Evaluate studies on prokinetic agents in preterm infants.
- Determine if these agents are beneficial and justified.
- Assess the efficacy of erythromycin for gastrointestinal dysmotility.
Main Methods:
- Review of randomized controlled trials.
- Investigation of erythromycin effectiveness.
- Analysis of low-dose, prophylactic, and high-dose regimens.
Main Results:
- Low-dose and prophylactic erythromycin were not effective.
- High-dose erythromycin as rescue therapy showed clinical benefit.
- Potential risks like antibiotic resistance were not fully evaluated.
Conclusions:
- High-dose erythromycin as rescue therapy is likely justifiable.
- Further research is needed for safer prokinetic agents.
- Development of novel agents with improved safety profiles is warranted.
Purpose Of Review:
Functional gastrointestinal dysmotility is a common condition that affects premature infants. Delay in achievement of full enteral nutrition results in dependence on prolonged parenteral nutrition, predisposing to adverse outcomes. Studies in recent years show apparently conflicting results regarding the use of prokinetic agents in preterm infants. This review aims to evaluate these studies to determine whether use of these agents in premature infants is beneficial and justified.
Recent Findings:
Randomized controlled trials in recent years have been performed to investigate the effectiveness of erythromycin in the treatment of nonobstructive gastrointestinal dysmotility in preterm infants. Overall, neither low-dose regimes nor prophylactic trials have been shown to be useful. High-dose regimes used as rescue therapy of infants with established gastrointestinal dysmotility have consistently shown clinical benefit. Theoretical risks of prolonged antibiotic use, such as emergence of antibiotic resistance and abnormal intestinal microbiota, have not been fully evaluated.
Summary:
Judicious use of high-dose erythromycin in premature infants as rescue therapy is probably justifiable. Further research in this area is warranted to develop newer prokinetic agents which may improve the safety profile of therapy.
More Related Videos
09:36Effect of Hyaluronic Acid 35 kDa on an In Vitro Model of Preterm Small Intestinal Injury and Healing Using Enteroid-Derived Monolayers
Published on: July 28, 2022
09:44Functional Assessment of Intestinal Motility and Gut Wall Inflammation in Rodents: Analyses in a Standardized Model of Intestinal Manipulation
Published on: September 11, 2012
Related Concept Videos
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
Drug Dosing: Infants and Children
Gastrointestinal Motility Disorders
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Pharmacokinetics in Pediatric Patients: Drug Excretion